RASSF1A: A potential novel therapeutic target against cardiac hypertrophy

Progress in Biophysics and Molecular Biology

Volumn 113, Issue 2, 2013, Pages 284-288

  Duan, Chenyang ^a   Liu, Mengying ^a   Zhang, Jiqiang ^a   Ma, Ruiyan ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cardiac hypertrophy; Heart failure; Ras association domain family 1 isoform A; Signaling pathway; Therapeutic strategy

Indexed keywords

CARDIOTONIC AGENT; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

BIOLOGICAL MODEL; CARDIOMEGALY; DRUG ANTAGONISM; DRUG EFFECT; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; RAS ASSOCIATION DOMAIN FAMILY 1 ISOFORM A; REVIEW; SIGNAL TRANSDUCTION; SIGNALING PATHWAY; THERAPEUTIC STRATEGY;

CARDIAC HYPERTROPHY; HEART FAILURE; RAS ASSOCIATION DOMAIN FAMILY 1 ISOFORM A; SIGNALING PATHWAY; THERAPEUTIC STRATEGY;

CARDIOMEGALY; CARDIOTONIC AGENTS; HUMANS; MODELS, CARDIOVASCULAR; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84887608131     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2013.07.004     Document Type: Review

References (54)

1. Agathanggelou A., Cooper W.N., Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005, 65:3497-3508.
2. Armesilla A.L., et al. Novel functional interaction between the plasma membrane Ca2+ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1). J.Biol. Chem. 2004, 279:31318-31328.
3. Cai J., et al. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 2010, 24:2383-2388.
4. Dallol A., et al. RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res. 2004, 64:4112-4116.
5. Dammann R., et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 2000, 25:315-319.
6. Dammann R., et al. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol. and Histopathol. 2005, 20:645-663.
7. Dammann R., et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol. Histopathol. 2003, 18:665-677.
8. Del Re D.P., et al. Proapoptotic Rassf1A/Mst1 signaling in cardiac fibroblasts is protective against pressure overload in mice. J.Clin. Invest. 2010, 120:3555-3567.
9. Del Re D.P., Sadoshima J. RASSF1A signaling in the heart: novel functions beyond tumor suppression. Mol. Biol. Int. 2012, 2012:154283.
10. Donninger H., Vos M.D., Clark G.J. The RASSF1A tumor suppressor. J.Cell Sci. 2007, 120:3163-3172.
11. Dorn G.W., Robbins J., Sugden P.H. Phenotyping hypertrophy: eschew obfuscation. Circ. Res. 2003, 92:1171-1175.
12. Fritz R.D., Radziwill G. The scaffold protein CNK1 interacts with the angiotensin II type 2 receptor. Biochem. Biophys. Res. Commun. 2005, 338:1906-1912.
13. Hamilton G., et al. ATM regulates a RASSF1A-dependent DNA damage response. Curr. Biol. 2009, 19:2020-2025.
14. Heallen T., et al. Hippo pathway Inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 2011, 332:458-461.
15. Hesson L.B., Cooper W.N., Latif F. The role of RASSF1A methylation in cancer. Dis. Markers 2007, 23:73-87.
16. Izumo S., Nadal-Ginard B., Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc. Natl. Acad. Sci. U S A 1988, 85:339-343.
17. Klingbeil A.U., et al. Ameta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 2003, 115:41-46.
18. Komuro I., et al. Expression of cellular oncogenes in the myocardium during the developmental stage and pressure-overloaded hypertrophy of the rat heart. Circ. Res. 1988, 62:1075-1079.
19. Li Y.C., Chen C.R., Chang E.C. Fission yeast Ras1 effector Scd1 interacts with the spindle and affects its proper formation. Genetics 2000, 156:995-1004.
20. Liu L.M., et al. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 2003, 22:8125-8136.
21. Liu L.Y., Vo A., McKeehan W.L. Specificity of the methylation-suppressed A isoform of candidate tumor suppressor RASSF1 for microtubule hyperstabilization is determined by cell death inducer C19ORF5. Cancer Res. 2005, 65:1830-1838.
22. Mitchell S., et al. Distinct gene expression profiles in adult mouse heart following targeted MAP kinase activation. Physiol. Genomics 2006, 25:50-59.
23. Mohamed T.M., et al. Plasma membrane calcium pump (PMCA4)-neuronal nitric-oxide synthase complex regulates cardiac contractility through modulation of a compartmentalized cyclic nucleotide microdomain. J.Biol. Chem. 2011, 286:41520-41529.
24. Mulvagh S.L., et al. Ahemodynamic load invivo induces cardiac expression of the cellular oncogene, c-myc. Biochem. Biophys. Res. Commun. 1987, 147:627-636.
25. Newton A.C. Protein kinase C. Seeing two domains. Curr. Biol. 1995, 5:973-976.
26. Oceandy D., et al. Tumor suppressor Ras-association domain family 1 isoform a is a novel regulator of cardiac hypertrophy. Circulation 2009, 120:607-616. U125.
27. Oceandy D., et al. The regulatory function of plasma-membrane Ca(2+)-ATPase (PMCA) in the heart. Biochem. Soc. Trans. 2007, 35:927-930.
28. Oh H.J., et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 2006, 66:2562-2569.
29. Ortiz-Vega S., et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002, 21:1381-1390.
30. Patra S.K., Szyf M. DNA methylation-mediated nucleosome dynamics and oncogenic Ras signaling - insights from FAS, FAS ligand and RASSF1A. Febs J. 2008, 275:5217-5235.
31. Pfeifer G.P., Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochem. -Moscow 2005, 70:576-583.
32. Pfeifer G.P., et al. Methylation of the RASSF1A gene in human cancers. Biol. Chem. 2002, 383:907-914.
33. Praskova M., et al. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem. J. 2004, 381:453-462.
34. Rajakulendran T., et al. Adimerization-dependent mechanism drives RAF catalytic activation. Nature 2009, 461:542-545.
35. Ren F., et al. Hippo signaling regulates Drosophila intestine stem cell proliferation through multiple pathways. Proc. Natl. Acad. Sci. U S A 2010, 107:21064-21069.
36. Richter A.M., Pfeifer G.P., Dammann R.H. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim. Biophys. Acta 2009, 1796:114-128.
37. Rodriguez-Viciana P., Sabatier C., McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell Biol. 2004, 24:4943-4954.
38. Sano M., et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448.
39. Saucedo L.J., Edgar B.A. Filling out the Hippo pathway. Nat. Rev. Mol. Cell Biol. 2007, 8:613-621.
40. Segal M., Clarke D.J. The Ras pathway and spindle assembly collide?. Bioessays 2001, 23:307-310.
41. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 2003, 3:155-168.
42. Song M.S., et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat. Cell Biol. 2004, 6:129-136.
43. Stoeger S.M., Cowan K.H. Characterization of kinase suppressor of Ras-1 expression and anticancer drug sensitivity in human cancer cell lines. Cancer Chemother. Pharmacol. 2009, 63:807-818.
44. Therrien M., Wong A.M., Rubin G.M. CNK, a RAF-binding multidomain protein required for RAS signaling. Cellule 1998, 95:343-353.
45. Tsutsui H., Ishihara K., Gt Cooper Cytoskeletal role in the contractile dysfunction of hypertrophied myocardium. Science 1993, 260:682-687.
46. Vos M.D., Clark G.J. RASSF family proteins and Ras transformation. Meth. Enzymol. 2006, 407:311-322.
47. Vos M.D., et al. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J.Biol. Chem. 2000, 275:35669-35672.
48. Wang Y.C., Yu Z.H., Chen L.B. Role of RASSF1A hypermethylation in prostate cancer. Zhonghua nan ke xue= Natl. J. Androl. 2007, 13:822-825.
49. Wu X., et al. Plasma membrane Ca2+-ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents. J.Clin. Invest. 2009, 119:976-985.
50. Xing X.S., Huang L.M., Ma X.D., et al. Progress of RASSF1A gene in neoplasms. Zhonghua bing li xue za zhi Chin. J. Pathol. 2004, 33:562-564.
51. Yamamoto S., et al. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J.Clin. Invest. 2003, 111:1463-1474.
52. Yin M., Zhang L. Hippo signaling: a hub of growth control, tumor suppression and pluripotency maintenance. J.Genet. Genomics 2011, 38:471-481.
53. Zhao B., Tumaneng K., Guan K.L. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat. Cell Biol. 2011, 13:877-883.
54. Zi M., et al. The sarcolemmal calcium pump (PMCA4b) is involved in the development of pressure overload induced hypertrophy. J.Mol. Cell Cardiol. 2007, 42:S137.